Loading...
•
Sep 30, 2020
ANI Pharmaceuticals Q3 2020 Earnings Report
ANI Pharmaceuticals reported third quarter results with net revenues of $53.0 million and net income of $0.4 million.
Key Takeaways
ANI Pharmaceuticals reported third quarter 2020 results with net revenues of $53.0 million, a net income of $0.4 million, and diluted EPS of $0.04. The company is on track with the Cortrophin® Gel sNDA re-filing and has a commercialization and operational launch readiness plan underway. A new CEO and Board members have been added to drive business growth.
Third quarter net revenues were $53.0 million.
Net income for the third quarter was $0.4 million, with diluted EPS of $0.04.
Adjusted non-GAAP diluted EPS was $0.97 for the third quarter.
Cortrophin Gel sNDA re-filing is on track with commercialization plans underway.
ANI Pharmaceuticals
ANI Pharmaceuticals
ANI Pharmaceuticals Revenue by Segment
Revenue by Segment
Brands Revenue
CapyFin.comGeneric Pharmaceutical Products Revenue
CapyFin.com Forward Guidance
The company anticipates that Cortrophin-related expenses in the fourth quarter of 2020 will be moderately higher than those of the third quarter, as they continue to focus on their sNDA resubmission efforts.
Revenue & Expenses
Visualization of income flow from segment revenue to net income